
Bristol-Myers Squibb Company: shareholders and insiders
Price
$58.34
November 19, 2026Market cap $119B
What Ploutos Investor adds for Bristol-Myers Squibb
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Reading the newest filings from the SEC. This part fills in on its own in a few seconds.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- AQR CapitalIn the quarter-9.0%
- Millennium Mgmt (Englander)In the quarter+193%
- Citadel Advisors (Griffin)In the quarter-27%
- D.E. ShawIn the quarter+105%
- Bridgewater (Dalio)In the quarter
- Renaissance TechnologiesIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| AQR Capital | 24.88M | -9.0% | $1.6B | 0.46% |
| Millennium Mgmt (Englander) | 2.20M | +193% | $138M | 0.10% |
| Citadel Advisors (Griffin) | 1.14M | -27% | $71M | 0.04% |
| D.E. Shaw | 1.15M | +105% | $72M | 0.04% |
| Bridgewater (Dalio) | 77.8K | $4.9M | 0.02% | |
| Renaissance Technologies | 18.2K | $1.1M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 2.45% of its shares outstanding were held short, +8.9% since the report before.
- Shares held short
- 49.95M
- 2.45%
- Since the report before45.85M on Sep 30, 2026
- +8.9%
- 3.7
- 13.69M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 43%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 23.40M
- Nov 15, 2023: Shares held short 26.80M
- Nov 30, 2023: Shares held short 27.17M
- Dec 15, 2023: Shares held short 24.10M
- Dec 29, 2023: Shares held short 22.31M
- Jan 12, 2024: Shares held short 29.19M
- Jan 31, 2024: Shares held short 31.09M
- Feb 15, 2024: Shares held short 31.49M
- Feb 29, 2024: Shares held short 32.65M
- Mar 15, 2024: Shares held short 37.25M
- Mar 28, 2024: Shares held short 35.12M
- Apr 15, 2024: Shares held short 34.36M
- Apr 30, 2024: Shares held short 28.02M
- May 15, 2024: Shares held short 28.27M
- May 31, 2024: Shares held short 28.73M
- Jun 14, 2024: Shares held short 30.29M
- Jun 28, 2024: Shares held short 31.62M
- Jul 15, 2024: Shares held short 32.06M
- Jul 31, 2024: Shares held short 26.42M
- Aug 15, 2024: Shares held short 28.01M
- Aug 30, 2024: Shares held short 22.26M
- Sep 13, 2024: Shares held short 21.79M
- Sep 30, 2024: Shares held short 20.03M
- Oct 15, 2024: Shares held short 22.50M
- Oct 31, 2024: Shares held short 23.42M
- Nov 15, 2024: Shares held short 25.77M
- Nov 29, 2024: Shares held short 25.60M
- Dec 13, 2024: Shares held short 27.66M
- Dec 31, 2024: Shares held short 24.93M
- Jan 15, 2025: Shares held short 27.52M
- Jan 31, 2025: Shares held short 26.70M
- Feb 14, 2025: Shares held short 25.59M
- Feb 28, 2025: Shares held short 30.57M
- Mar 14, 2025: Shares held short 37.01M
- Mar 31, 2025: Shares held short 29.40M
- Apr 15, 2025: Shares held short 30.03M
- Apr 30, 2025: Shares held short 37.12M
- May 15, 2025: Shares held short 37.01M
- May 30, 2025: Shares held short 32.54M
- Jun 13, 2025: Shares held short 33.61M
- Jun 30, 2025: Shares held short 39.45M
- Jul 15, 2025: Shares held short 38.38M
- Jul 31, 2025: Shares held short 30.92M
- Aug 15, 2025: Shares held short 29.69M
- Aug 29, 2025: Shares held short 31.19M
- Sep 15, 2025: Shares held short 29.47M
- Sep 30, 2025: Shares held short 26.34M
- Oct 15, 2025: Shares held short 30.36M
- Oct 31, 2025: Shares held short 32.07M
- Nov 14, 2025: Shares held short 31.69M
- Nov 28, 2025: Shares held short 33.89M
- Dec 15, 2025: Shares held short 35.43M
- Dec 31, 2025: Shares held short 36.58M
- Jan 15, 2026: Shares held short 36.98M
- Jan 30, 2026: Shares held short 29.89M
- Feb 13, 2026: Shares held short 31.67M
- Feb 27, 2026: Shares held short 33.42M
- Mar 13, 2026: Shares held short 29.85M
- Mar 31, 2026: Shares held short 31.50M
- Apr 15, 2026: Shares held short 32.39M
- Apr 30, 2026: Shares held short 31.33M
- May 15, 2026: Shares held short 36.72M
- May 29, 2026: Shares held short 38.51M
- Jun 15, 2026: Shares held short 39.60M
- Jun 30, 2026: Shares held short 40.53M
- Jul 15, 2026: Shares held short 44.94M
- Jul 31, 2026: Shares held short 52.34M
- Aug 14, 2026: Shares held short 45.85M
- Aug 31, 2026: Shares held short 44.07M
- Sep 15, 2026: Shares held short 41.97M
- Sep 30, 2026: Shares held short 45.85M
- Oct 15, 2026: Shares held short 49.95M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading41.7% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 41.7% of the shares in the reported trades were short sales, against 47.3% in the 14 before.
- Last 14 sessionsNov 2, 2026 – Nov 19, 2026
- 41.7%
- The 14 beforeOct 13, 2026 – Oct 30, 2026
- 47.3%
- Change
- -5.6 pts
- Short sales a dayon average, of 3.53M shares
- 1.47M
- More than atof 3,666 US-listed companies, same days
- 24%
- Median of alleight in ten from 34.5% to 63.8%
- 50.4%
- Short sales
- Oct 13, 2026: Short sales 42.8%
- Oct 14, 2026: Short sales 44%
- Oct 15, 2026: Short sales 39.3%
- Oct 16, 2026: Short sales 35.7%
- Oct 19, 2026: Short sales 36.6%
- Oct 20, 2026: Short sales 59.6%
- Oct 21, 2026: Short sales 51.3%
- Oct 22, 2026: Short sales 51.3%
- Oct 23, 2026: Short sales 58.2%
- Oct 26, 2026: Short sales 51.7%
- Oct 27, 2026: Short sales 59.4%
- Oct 28, 2026: Short sales 56.5%
- Oct 29, 2026: Short sales 45%
- Oct 30, 2026: Short sales 48.7%
- Nov 2, 2026: Short sales 32.2%
- Nov 3, 2026: Short sales 29.9%
- Nov 4, 2026: Short sales 26.2%
- Nov 5, 2026: Short sales 46.8%
- Nov 6, 2026: Short sales 50.6%
- Nov 9, 2026: Short sales 44.8%
- Nov 10, 2026: Short sales 51.5%
- Nov 11, 2026: Short sales 52.5%
- Nov 12, 2026: Short sales 45.1%
- Nov 13, 2026: Short sales 53.1%
- Nov 16, 2026: Short sales 54.6%
- Nov 17, 2026: Short sales 32.2%
- Nov 18, 2026: Short sales 49.5%
- Nov 19, 2026: Short sales 38.3%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
10b5-1 trading plans
Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.
- David V. ElkinsChief Financial OfficerWhat happenedAdoptedJun 3, 2025Shares86.0K
| Person | What happened | Until | Shares | Filing |
|---|---|---|---|---|
| David V. ElkinsChief Financial Officer | AdoptedJun 3, 2025 | May 1, 2026 | 86.0K | 10-Q |
As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.
Executive pay
From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.
$22M
Actually paid: $17M
$9.2M
Actually paid: $7.3M
$105
Peers: $198
total revenues
$48.2B
From the proxy statement (DEF 14A) of Mar 25, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A
Share repurchases
How many of its own shares the company bought each quarter, at what average price, for how much, and what remains of the program its board authorized, from the table it puts in every 10-Q and 10-K.
- Sep 30, 202310-QAmount$4.1B
- Jun 30, 202310-QAmount$914M
- Dec 31, 202210-KAmount$2.3B
- Sep 30, 202210-QAmount$708M
- Dec 31, 202110-KAmount$2.8B
- Sep 30, 202110-QAmount$501M
- Jun 30, 202110-QAmount$1.3B
- Mar 31, 202110-QAmount$2.0B
| Quarter | Shares | Average price | Amount | Left in the program | Filing |
|---|---|---|---|---|---|
| Sep 30, 202310-Q | 112.36B | $0.04 | $4.1B | $2.0B | 10-Q |
| Jun 30, 202310-Q | 26.89M | $33.98 | $914M | $6.0B | 10-Q |
| Dec 31, 202210-K | 60.95M | $37.83 | $2.3B | $7.2B | 10-K |
| Sep 30, 202210-Q | 24.67M | $28.71 | $708M | $9.5B | 10-Q |
| Dec 31, 202110-K | 97.66M | $28.84 | $2.8B | $15.2B | 10-K |
| Sep 30, 202110-Q | 14.86M | $33.75 | $501M | $2.9B | 10-Q |
| Jun 30, 202110-Q | 39.35M | $32.58 | $1.3B | $3.4B | 10-Q |
| Mar 31, 202110-Q | 62.67M | $31.25 | $2.0B | $4.6B | 10-Q |
From the "Issuer Purchases of Equity Securities" table of the 10-Qs and 10-Ks, read without a model. Only the quarters whose shares times average price agree with the cash the company says it paid for repurchases in its cash-flow statement are shown. The shares include those withheld for officers' taxes. A quarter with an accelerated repurchase shows the table's shares and the cash paid, without an average price. 14 filing(s) not shown, as the table was not read or did not agree with the cash.
The shareholders' vote on pay
The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.
- 2026May 8, 2026For95.3%
- 2025May 7, 2025For94.0%
- 2024May 9, 2024For94.4%
- 2023May 4, 2023For92.4%
- 2022May 5, 2022For91.9%
- 2021May 6, 2021For91.1%
| Year | For | Votes for | Votes against | Abstentions | Broker non-votes | Filing |
|---|---|---|---|---|---|---|
| 2026May 8, 2026 | 95.3% | 1.46B | 72.49M | 6.93M | 235M | 8-K |
| 2025May 7, 2025 | 94.0% | 1.44B | 92.01M | 5.81M | 242M | 8-K |
| 2024May 9, 2024 | 94.4% | 1.40B | 82.96M | 7.84M | 267M | 8-K |
| 2023May 4, 2023 | 92.4% | 1.44B | 118M | 6.88M | 269M | 8-K |
| 2022May 5, 2022 | 91.9% | 1.42B | 126M | 7.30M | 280M | 8-K |
| 2021May 6, 2021 | 91.1% | 1.45B | 142M | 7.25M | 310M | 8-K |
From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- PPHVanEck Pharmaceutical ETFWeight in the fund4.47%
- IHEiShares U.S. Pharmaceuticals ETFWeight in the fund4.37%
- FDLFirst Trust Morningstar Dividend Leaders Index FundWeight in the fund3.43%
- SCHDSchwab U.S. Dividend Equity ETFWeight in the fund3.32%
- HDViShares Core High Dividend ETFWeight in the fund2.70%
- MOATVanEck Morningstar Wide Moat ETFWeight in the fund2.43%
- IYHiShares U.S. Healthcare ETFWeight in the fund2.20%
- COWZPacer US Cash Cows 100 ETFWeight in the fund2.18%
- SPHDInvesco S&P 500 High Dividend Low Volatility ETFWeight in the fund2.13%
- XLVState Street(R) Health Care Select Sector SPDR(R) ETFWeight in the fund2.05%
64 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 2,278
- Q4 2025: Managers 2,460
- Q1 2026: Managers 2,542
- Q2 2026: Managers 2,517
Institutional investors by quarter
The fund managers holding BMY, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 2,517 managers held 1.67B shares, worth $96.5B. During the quarter 173 opened a position, 198 closed one, 968 added and 977 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+5.1%
- Vanguard Capital ManagementIn the quarter+0.8%
- State StreetIn the quarter+3.9%
- JPMorgan ChaseIn the quarter-22%
- Charles Schwab Investment ManagementIn the quarter+11%
- Geode Capital ManagementIn the quarter+2.1%
- Vanguard Portfolio ManagementIn the quarter+1.4%
- Norges BankIn the quarter+2.1%
- Bank of AmericaIn the quarter+4.5%
- Price T Rowe AssociatesIn the quarter+209%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 180M | +5.1% | $10.4B |
| Vanguard Capital Management | 133M | +0.8% | $7.7B |
| State Street | 102M | +3.9% | $5.9B |
| JPMorgan Chase | 71.71M | -22% | $4.2B |
| Charles Schwab Investment Management | 67.60M | +11% | $3.9B |
| Geode Capital Management | 56.44M | +2.1% | $3.2B |
| Vanguard Portfolio Management | 46.87M | +1.4% | $2.7B |
| Norges Bank | 36.87M | +2.1% | $2.1B |
| Bank of America | 34.05M | +4.5% | $2.0B |
| Price T Rowe Associates | 31.71M | +209% | $1.8B |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
The full analysis
What do Bristol-Myers Squibb's filings show?
Who buys and sells is one part of Bristol-Myers Squibb's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Which well-known managers hold BMY?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $1.6B.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.